Download App

Log in to access Online Inquiry
Company Overview More
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
CEO: Astley-Sparke FSA, Philip
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > REPL Replimune > Detailed Quotes

REPL Replimune

14.120+0.220+1.58%
Close 05/26 20:00 ET
High
14.462
Open
13.940
Turnover
2.33M
Low
13.940
Pre Close
13.900
Volume
164.13K
Market Cap
692.87M
P/E(TTM)
Loss
52wk High
40.220
Shares
49.07M
P/E(Static)
Loss
52wk Low
13.050
Float Cap
401.09M
Bid/Ask %
0.00%
Historical High
54.850
Shs Float
28.41M
Volume Ratio
0.51
Historical Low
8.580
Dividend TTM
--
Div Yield TTM
10
P/B
1.68
Dividend LFY
--
Div Yield LFY
70.82%
Turnover Ratio
0.58%
Amplitude
3.76%
Avg Price
14.177
Lot Size
1
Float Cap
401.09M
Bid/Ask %
0.00%
Historical High
54.850
Shs Float
28.41M
Volume Ratio
0.51
Historical Low
8.580
Dividend TTM
--
P/B
1.68
Dividend LFY
--
Turnover Ratio
0.58%
Amplitude
3.76%
Avg Price
14.177
Lot Size
1
Price Forecast

No Data

News

Comment